Death receptor-mediated suicide: a novel target of autoimmune disease treatment

Bibliography

• DE MARIA R, TESTI R: Fas-FasL interactions: a common pathogenetic mechanism in organ- specific autoim-munity. Immunol. Today. (1998) 19(3):121–125.
   PubMedGoogle Scholar
• MCDEVITT HO: The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr. Opin. Immunol. (1998) 10 (6) :677–681.
   PubMed Web of Science ®Google Scholar
• O'GARRA A, STEINMAN L, GIJBELS K: CD4+ T-cell subsets in autoimmunity. Curr. Opin. Immunol. (1997) 9(6):872–883.
   PubMed Web of Science ®Google Scholar
• TIAN J, OLCOTT A, HANSSEN L et al: Antigen-based immunotherapy for autoimmune disease: from animal models to humans? Immunol. Today. (1999) 2O(4):190–195.
   Google Scholar
• PARRY SL, HALL FC, OLSON J et al: Autoreactivity versus autoaggression: a different perspective on human autoantigens. Curr. Opin. Immunol. (1998) 10(6):663–668.
   PubMed Web of Science ®Google Scholar
• KUCHROO VK, WEINER HL: Antigen-driven regulation of experimental autoimmune encephalomyelitis. Res. Immunol (1998) 149(9):759–771; discussion 842–753, 855–760.
   Google Scholar
• WALDMANN H, COBBOLD S: How do monoclonalantibodies induce tolerance? A role for infectious tolerance. Ann. Rev. Immunol. (1998) 16:619–644.
   PubMed Web of Science ®Google Scholar
• BRUNNER T, GENESTIER L: DATELINE Aix-les-bains. Cell Death Differ. (1998) 5(6):539–546.
   PubMed Web of Science ®Google Scholar
• SLOAN-LANCASTER J, ALLEN PM: Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Ann. Rev. Immunol. (1996) 14:1–27.
   PubMed Web of Science ®Google Scholar
• SINGER NG, MCCUNE WJ: Update on immunosuppres-sive therapy. Curr. Opin. Rheumatol. (1998) 10(3):169–173.
   PubMedGoogle Scholar
• BUTZ EA, BEVAN MJ: Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity. (1998) 8(2):167–175.
   PubMed Web of Science ®Google Scholar
• •Assessment of the extent of antigen-specific T-cell expansion.
   Google Scholar
• MURALI-KRISHNA K, ALTMAN JD, SURESH M et al: Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity (1998) 8(2):177–187.
   PubMed Web of Science ®Google Scholar
• •Assessment of the extent of antigen-specific T-cell expansion.
   Google Scholar
• MOUNTZ JD, ZHOU T, SU X et al.: The role ofprogrammed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin. Immunol. Immunopathol (1996) 80(3 Pt 2):S2–14.
   Google Scholar
• VAN PARIJS L, ABBAS AK: Homeostasis and self-tolerance in the immune system: turning lympho-cytes off. Science. (1998) 280(5360:243–248.
   PubMedGoogle Scholar
• •Overview on the role of AICD in T-cell regulation.
   Google Scholar
• O'REILLY LA, STRASSER A: Apoptosis and autoimmunedisease. Inflamm. Res. (1999) 48(0:5–21.
   PubMed Web of Science ®Google Scholar
• BRUNNER T, MOGIL RJ, LA FACE D et al.:Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (1995) 373(6513):441–444.
   Google Scholar
• •First demonstration of cell-autonomous suicide in T-cells.
   Google Scholar
• BRUNNER T, Y00 NJ, LA FACE D et al.: Activation- induced cell death in murine T cell hybridomas. Differ-ential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int. Immunol. (1996) 8(7):1017–1026.
   Google Scholar
• •First demonstration of cell-autonomous suicide in T-cells.
   Google Scholar
• DHEIN J, WALCZAK H, BAUMLER C et al.: Autocrine T-cellsuicide mediated by APO-1/Fas (CD95). Nature (1995) 373:438–441.
   PubMed Web of Science ®Google Scholar
• JU ST, PANKA DJ, CUI H et al.: FasaCD95)/FasL interac-tions required for programmed cell death after T-cell activation. Nature (1995) 373:444–448.
   PubMed Web of Science ®Google Scholar
• ALDERSON MR, TOUGH TW, DAVIS-SMITH T et al.: Fasligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. (1995) 181):71–77.
   PubMed Web of Science ®Google Scholar
• SU X, CHENG J, LIU W et al: Autocrine and paracrineapoptosis are mediated by differential regulation of Fas ligand activity in two distinct Jurkat T cell popula-tions. J. Immunol. (1998) 160(10:5288–5293.
   PubMedGoogle Scholar
• BRUNNER T, Y00 NJ, GRIFFITH TS et al.: Regulation of CD95 ligand expression: a key element in immune regulation? Behring Inst. Mitt. (1996) 97:161–174.
   Google Scholar
• MARIANI SM, MATIBA B, BAUMLER C et al.: Regulation of cell surface APO-1/Fas aCD95) ligand expression by metalloproteases. Eur. j Immunol. (1995) 25:2303–2307.
   PubMed Web of Science ®Google Scholar
• SUDA T, HASHIMOTO H, TANAKA M et al: MembraneFas ligand kills human peripheral blood T lympho-cytes, and soluble Fas ligand blocks the killing. J. Exp. Med. (1997) 186(12):2045–2050.
   PubMed Web of Science ®Google Scholar
• •Demonstration that membrane-bound and soluble CD95L have distinct functions.
   Google Scholar
• TANAKA M, SUDA T, TAKAHASHI T et al.: Expression ofthe functional soluble form of human fas ligand in activated lymphocytes. EMBOJ (1995) 14(6):1129–1135.
   PubMed Web of Science ®Google Scholar
• TANAKA M, ITAI T, ADACHI M et al.: Downregulation ofFas ligand by shedding. Nature Med. (1998) 4(1):31–36.
   PubMed Web of Science ®Google Scholar
• CHENG J, ZHOU T, LIU C et al.: Protection fromfas-mediated apoptosis by a soluble form of the fas molecule. Science (1994) 263:1759–1762.
   PubMed Web of Science ®Google Scholar
• •First demonstration that soluble CD95 is involved in autoim-mune disease.
   Google Scholar
• CASCINO I, FIUCCI G, PAPOFF G et al: Three functionalsoluble forms of the human apoptosis-inducing fas molecule are produced by alternative splicing. J. Immunol. (1995) 154:2706–2713.
   PubMed Web of Science ®Google Scholar
• CASCINO I, PAPOFF G, DE MARIA R et al: Fas/Apo-1(CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from fas-mediated apoptosis. J. Immunol. (1996) 156:13–17.
   PubMed Web of Science ®Google Scholar
• NAGATA S, SUDA T: Fas and fas ligand: lpr and gldmutations. Immunol. Today. (1995) 16(1)39–43.
   Google Scholar
• RUSSELL JH, RUSH B, WEAVER C et al.: Mature T cells ofautoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. USA (1993) 90(104409–4413.
   Google Scholar
• •First demonstration of the effect of the lpr mutation in AICD.
   Google Scholar
• MOGIL RJ, RADVANYI L, GONZALEZ-QUINTIAL R et al:Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int. Immunol. (1995) 7(9):1451–1458.
   PubMed Web of Science ®Google Scholar
• SINGER GG, CARRERA AC, MARSHAK-ROTHSTEIN A et al.:Apoptosis, fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr. Opin. Immunol. (1994) 6:913–920.
   PubMed Web of Science ®Google Scholar
• SINGER GG, ABBAS AK: The fas antigen is involved inperipheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity (1994) 1 (5):365–371.
   PubMed Web of Science ®Google Scholar
• •Demonstrates the importance of CD95 in antigen-induced peripheral deletion.
   Google Scholar
• SPEISER DE, SEBZDA E, OHTEKI T et al.: Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur. J. Immunol. (1996) 26(12)3055–3060.
   Google Scholar
• ZHENG L, FISHER G, MILLER RE et al.: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (1995) 377:348–351.
   PubMed Web of Science ®Google Scholar
• ASHKENAZI A, DIXIT VM: Apoptosis control by death and decoy receptors. Curr. Opin. Cell. Biol. (1999) 11(2):255–260.
   PubMed Web of Science ®Google Scholar
• •Review on death-inducing receptors.
   Google Scholar
• KING C, SARVETNICK N: Organ-specific autoimmunity. Curr. Opin. Immunol. (1997) 9(6):863–871.
   PubMed Web of Science ®Google Scholar
• MOUNTZ JD, EDWARDS CK: Murine models of autoim-munity: T-cell and B-cell defects. Curr. Opin. Rheumatol. (1992) 4(5):612–620.
   PubMedGoogle Scholar
• WU J, ZHOU T, ZHANG J eta].: Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc. Natl. Acad. Sci. USA (1994) 91:2344–2348.
   Google Scholar
• ZHOU T, ILL CKE, MOUNTZ JD: Prevention of age-related T cell apoptosis defect in CD2-fas-transgenic mice. J. Exp. Med. (1995) 182:129–137.
   PubMed Web of Science ®Google Scholar
• RIEUX-LAUCAT F, LE DEIST F, HIVROZ C et al.: Mutations in fas associated with human lymphoproliferative syndrome and autoimmunity. Science. (1995) 268:1347–1349.
   PubMed Web of Science ®Google Scholar
• •One of the first demonstrations that genetic defects of CD95 can cause autoimmune disease.
   Google Scholar
• VAISHNAW AK, ORLINICK JR, CHU JL et al.: The molecular basis for apoptotic defects in patients with CD95. J. Clin. Invest. (1999) 103(3):355–363.
   PubMed Web of Science ®Google Scholar
• NAGATA S: Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J. Hum. Genet. (1998) 43(0:2–8.
   PubMed Web of Science ®Google Scholar
• VAN PARIJS L, BIUCKIANS A, ABBAS AK: Functional roles of Fas and Bc1-2-regulated apoptosis of T lymphocytes. Immunol (1998) 160(5)2065–2071.
   Google Scholar
• PETSCHNER F, ZIMMERMAN C, STRASSER A et al. Consti- tutive expression of Bc1-xL or Bc1-2 prevents peptide antigen- induced T cell deletion but does not influence T cell homeostasis after a viral infection. Eur. J. Immunol. (1998) 28(2):560–569.
   PubMed Web of Science ®Google Scholar
• STRASSER A, HARRIS AW, HUANG DC et al.: Bc1-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J (1995) 14):6136–6147.
   PubMed Web of Science ®Google Scholar
• SCHROTER M, LOWIN B, BORNER C et al.: Regulation of Fas (Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bc1-2. Eur. J. Immunol. (19 9 5) 25(12):3509–3513.
   Google Scholar
• IWAI OK, MIYAWAKI T, TAKIZAWA T et al. Differential expression of bc1-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood (1 9 9 4) 84(4) 1201-1208
   Google Scholar
• MEMON SA, MORENO BM, PETRAK D et al. Bc1-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma. J. Immunol. (1995) 155:4644–4652.
   PubMed Web of Science ®Google Scholar
• CHIU VK, WALSH CM, LIU C-C et al.: Bc1-2 blocks degranulation but not fas-based cell-mediated cytotox-icily. JImmunol. (1995) 154:2023–2032.
   PubMed Web of Science ®Google Scholar
• ALAM MK, DAVISON S, SIDDIQUI N eta].: Ectopic expres-sion of Bc1-2, but not Bc1-xL rescues Ramos B cells from Fas-mediated apoptosis. Eur. J. Immunol. (1997) 2 7 (12):3485–3491.
   Google Scholar
• RODRIGUEZ I, MATSUURA K, KHATIB K et al.: A bc1-2 transgene expressed in hepatocytes protects mice from ftdminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J. Exp. Med. (1996) 183(3):1031–1036.
   PubMed Web of Science ®Google Scholar
• KAWAHARA A, KOBAYASHI T, NAGATA S: Inhibition of Fas-induced apoptosis by Bc1-2. Oncogene (1998) 1 7(20):2549–2554.
   Google Scholar
• STRASSER A: Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Curr. Opin. Immunol. (1995) 7:228–234.
   PubMed Web of Science ®Google Scholar
• TAMURA A, KATSUMATA M, GREENE MI et al.: Inhibition of apoptosis and augmentation of lymphoprolifera-tion in bc1-2 transgenic Fas/Fas ligand-defective mice. Cell Immunol. (1996) 168(2):220–228.
   PubMed Web of Science ®Google Scholar
• REAP EA, FELIX NJ, WOLTHUSEN PA et al.: bc1-2 transgenic Lpr mice show profound enhancement of lymphadenopathy.J.Immunol.(1 9 9 5)155(10:5455-5462.
   Google Scholar
• SATO T, IRIE S, KITADA S et al.: FAP-1: a protein tyrosine phosphatase that associates with fas. Science (1995) 268:411–415.
   PubMed Web of Science ®Google Scholar
• •Identification of the first CD95-specific inhibitory molecule.
   Google Scholar
• ITOH N, NAGATA S: A novel protein domain required for apoptosis. Mutational analysis of human fas antigen. J. Biol. Chem. (1993) 268(15):10932–10937.
   Web of Science ®Google Scholar
• MEDEMA JP, SCAFFIDI C, KISCHKEL FC et al.: FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). Embo J. (1 9 9 7) 16(102794–2804.
   Google Scholar
• •Biochemical analysis of the CD95 signalling complex.
   Google Scholar
• SCAFFIDI C, SCHMITZ I, KRAMMER PH et al.: The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. (1999) 2 74 (3):1541–1548.
   Google Scholar
• IRMLER M, THOME M, HAHNE M et al.: Inhibition of death receptor signals by cellular FLIP. Nature (1997) 388(6638):190–195.
   PubMed Web of Science ®Google Scholar
• •One of the first reports of the caspase 8 antagonsing molecule.
   Google Scholar
• ZHOU YW, KOMADA Y, INABA H et al.: Down-regulation of Fas-associated phosphatase-1 (FAP-1) in interleukin- 2-activated T cells. Cell Immunol (1998) 186(2):103–110.
   PubMed Web of Science ®Google Scholar
• REFAELI Y, VAN PARIJS L, LONDON CA et al: Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity (1998) 8(5):615–623.
   PubMed Web of Science ®Google Scholar
• •Role of cytokines in modulating sensitivity to AICD.
   Google Scholar
• HITOSHI Y, LORENS J, KITADA SI et al: Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity (1998) 8(4) :461–471.
   PubMed Web of Science ®Google Scholar
• ZHOU T, SONG L, YANG P et al.: Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nature Med. (1999) 5:42–48.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of the therapeutical use of a drug facili-tating AICD.
   Google Scholar
• RUIZ-RUIZ MC, IZQUIERDO M, DE MURCIA G et al: Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis. Eur. J. Immunol (1997) 2 7 (6) :1442–1450.
   Google Scholar
• TOKER A: Signaling through protein kinase C. Front Biosci. (1998) 1(3):D1134–1147.
   Google Scholar
• ••Thorough review on the protein kinase C family.
   Google Scholar
• DREW L, KUMAR R, BANDYOPADHYAY D et al Inhibi-tion of the protein kinase C pathway promotes anti-CD95-induced apoptosis in Jurkat cells. Int. Immunol. (1998) 1O(7):877–889.
   Web of Science ®Google Scholar
• FRIESEN C, HERR I, KRAMMER PH et al. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. (1996) 2(5):574–577.
   PubMed Web of Science ®Google Scholar
• KASIBHATLA S, BRUNNER T, GENESTIER L et al: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activa-tion of NF-kappa B and AP-1. Mot. Cell. (1998) 1(4):543–551.
   PubMed Web of Science ®Google Scholar
• •Demonstration that DNA damage can activate the CD95L promoter.
   Google Scholar
• SUDA T, TANAKA M, MIWA K et al: Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. Immunol (1996) 15 7 (9):3918–3924.
   Google Scholar
• KLAS C, DEBATIN K-M, JONKER RR et al.: Activation interferes with the APO-1 pathway in mature human T cells. mt. Immunol (1993) 5(8):625–630.
   Google Scholar
• BEG AA, BALTIMORE D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 274(5288):782–784.
   PubMed Web of Science ®Google Scholar
• VAN ANTWERP DJ, MARTIN SJ, KAFRI T et al.: Suppres- sion of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 274(5288):787–789.
   PubMed Web of Science ®Google Scholar
• WANG CY, MAYO MW, BALDWIN AS, JR.: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 274(5288)784–787.
   Google Scholar
• WANG CY, MAYO MW, KORNELUK RG et al.: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c- IAP2 to suppress caspase-8 activation. Science (1998) 281(5383)1680–1683.
   Google Scholar
• •Identification of the anti-apoptotic mechanism involving NFKB and c-IAPs.
   Google Scholar
• CHU ZL, MCKINSEY TA, LIU L et al.: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. USA (1997) 94 (19) :10057–10062.
   PubMed Web of Science ®Google Scholar
• LI F, AMBROSINI G, CHU EY et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 396(6710:580–584.
   PubMedGoogle Scholar
• TAMM I, WANG Y, SAUSVILLE E et al.: IAP-family protein survivin inhibits caspase activity and apoptosis. Cancer Res. (1998) 58(23)5315–5320.
   Google Scholar
• DUDLEY E, HORNUNG F, ZHENG L et al: NF-kappaB regulates Fas/AP0-1/CD95- and TCR- mediated apoptosis of T lymphocytes. Eur. J. Immunol. (1999) 29(3)878–886.
   Google Scholar
• MARTIN SJ, GREEN DR: Protease activation during apoptosis: death by a thousand cuts? Cell (1995) 82 (3):349–352.
   PubMed Web of Science ®Google Scholar
• LACASSE EC, BAIRD S, KORNELUK RG et al: The inhibi-tors of apoptosis (IAPs) and their emerging role in cancer. Oncogene (1998) 17(25):3247–3259.
   PubMed Web of Science ®Google Scholar
• BRUNNER T, MUELLER C: Is autoimmunity coming to a Eased) end? Nature Med. (1999) 5(0:19–20.
   Google Scholar
• RAMSDELL F, SEAMAN MS, MILLER RE et al.: Differential ability of Thl and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int. Immunol (1994) 6(101545–1553.
   Web of Science ®Google Scholar
• ZHANG X, BRUNNER T, CARTER L et al.: Unequal death in T helper cell (Th)1 and Th2 effectors: Thl, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. (1997) 185(10):1837–1849.
   PubMed Web of Science ®Google Scholar
• YANAGISAWA J, TAKAHASHI M, KANKI H et al.: The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J. Biol. Chem. (1997) 272(13)8539–8545.
   Google Scholar
• •Demonstration of the therapeutical use of inhibitors of protein-protein interaction.
   Google Scholar
• MCGAHON AJ, NISHIOKA WK, MARTIN SJ et al: Regula- tion of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. (1995) 270(38):22625–22631.
   PubMed Web of Science ®Google Scholar
• JANSEN B, SCHLAGBAUER-WADL H, BROWN BD et al: bc1-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. (1 9 9 8) 4 (2):232–234.
   Google Scholar
• LINT, BRUNNER T, TIETZ B et al.: Fas ligand- mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. J. Clin. Invest. (1998) 1O1(3):570–577.
   Google Scholar
• KONDO T, SUDA T, FUKUYAMA H et al.: Essential roles of the Fas ligand in the development of hepatitis. Nature Med. (1997) 3 (4) :409–413.
   PubMed Web of Science ®Google Scholar
• WALKER PR, SAAS P, DIETRICH PY: Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. (1997) 158(104521–4524.
   Google Scholar
• •Review on CD95L expressed in different types of tumours.
   Google Scholar
• MARTIN DA, ZHENG L, SIEGEL RM et al.: Defective CD95/AP0-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, Type Ia. Proc. Natl Acad. ScL USA (1999) 96(8) :4552–4557.
   PubMed Web of Science ®Google Scholar
• VAN LOPIK T, BIJL M, HART M et al: Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. J. Rheumatol. (1999) 26(0:60–67.
   PubMedGoogle Scholar